Literature DB >> 11564493

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.

G Klinger, Y Morad, C A Westall, C Laskin, K A Spitzer, G Koren, S Ito, R J Buncic.   

Abstract

Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugsduring pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564493     DOI: 10.1016/S0140-6736(01)06004-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

Review 1.  Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future.

Authors:  Fokaline Vroom; Hermien E K de Walle; Mart A J F van de Laar; Jacobus R B J Brouwers; Lolkje T W de Jong-van den Berg
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.

Authors:  Christina Chambers; Gideon Koren; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

Review 3.  Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.

Authors:  Ashima Makol; Kerry Wright; Shreyasee Amin
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 4.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

5.  Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.

Authors:  Monica Vaccari; Claudio Fenizia; Zhong-Min Ma; Anna Hryniewicz; Adriano Boasso; Melvin N Doster; Christopher J Miller; Niklas Lindegardh; Joel Tarning; Alan L Landay; Gene M Shearer; Genoveffa Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  2013-12-24       Impact factor: 2.205

Review 6.  The management of rheumatic diseases in pregnancy.

Authors:  K Mitchell; M Kaul; Megan E B Clowse
Journal:  Scand J Rheumatol       Date:  2010-03       Impact factor: 3.641

Review 7.  Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding.

Authors:  Nicole Bitencourt; Bonnie L Bermas
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 8.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 9.  Management of RA medications in pregnant patients.

Authors:  Monika Østensen; Frauke Förger
Journal:  Nat Rev Rheumatol       Date:  2009-06-09       Impact factor: 20.543

Review 10.  Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.

Authors:  Yusuf Cem Kaplan; Jak Ozsarfati; Cheri Nickel; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2016-02-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.